News|Articles|December 26, 2023

Continuing Medical Education 2023

Reviewing a year of CMEs in Psychiatric Times®

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Developing Next-Generation Psychedelic Treatments: Insights on Bretisilocin From AJ Cannon, MD

ByLeah Kuntz,AJ Cannon, MD

June 10th 2026

Monoamines: A Full House

ByJohn J. Miller, MD

June 10th 2026

“Engineered Addiction”: Redefining Addictive Disorders and the Psychiatric Impact of Social Media

ByLeah Kuntz

June 8th 2026

AI-Driven Biomarker Discovery from Wearables in Neuropsychiatric Research

ByMark Gerstein, PhD

June 5th 2026

Insights Into Mechanism-Based Biomarkers for Psychosis Prediction from Kim Do, PhD

ByKim Do, PhD,Jessica Walters

June 3rd 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Continuing Medical Education 2023

Related Content

Developing Next-Generation Psychedelic Treatments: Insights on Bretisilocin From AJ Cannon, MD

Monoamines: A Full House

“Engineered Addiction”: Redefining Addictive Disorders and the Psychiatric Impact of Social Media

AI-Driven Biomarker Discovery from Wearables in Neuropsychiatric Research

Insights Into Mechanism-Based Biomarkers for Psychosis Prediction from Kim Do, PhD

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Developing Next-Generation Psychedelic Treatments: Insights on Bretisilocin From AJ Cannon, MD

Artificial Intelligence in Psychopharmacology: Promise and Pitfalls, With Roy Perlis, MD

ALTO-203, an H3 Inverse Agonist, in Depression: Biomarker and Pharmacodynamic Findings

Addressing Sexual Wellness: A Psychiatric Perspective

What Do Orexin-2 Receptor Agonists Mean for Psychiatry?